APP and Alzheimer disease: In addition, EGCG intervention in APP/PS1 transgenic rats, a commonly used model for studying Alzheimer’s disease, further showed that the expression levels of TLR4 and NF-κB were reduced after EGCG treatment, indicating that EGCG reduced the inflammatory response and decreased neurotoxicity [37].